RaneeMehraMD

Oncology • Baltimore, MD

Head & Neck Cancer, Thoracic Cancer

Professor of Medicine

Join to view full profile

Dr. Mehra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mehra's full profile

Already have an account?

Office
22 S. Greene St.
Baltimore, MD 21201
Is this information wrong?

Summary

Solid Tumor Section Head, Director of Head and Neck Oncology

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
NYU Grossman School of MedicineResidency, Internal Medicine, 1999 - 2002
New York University School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2016 - 2025
DC State Medical License 2017 - 2018
PA State Medical License 2006 - 2016
CT State Medical License 2002 - 2006
NY State Medical License 2001 - 2003

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Dec 16
Completed
Phase 1
Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab Start of enrollment: 2010 Aug 05
Completed
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Start of enrollment: 2011 Feb 16
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Start of enrollment: 2013 Jun 01
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Start of enrollment: 2019 Jan 10
Active, not recruiting
Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Start of enrollment: 2019 May 07
Recruiting
Phase 2
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Terminated
Phase 2
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Start of enrollment: 2020 Jan 13
Active, not recruiting
Phase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Start of enrollment: 2020 Oct 13
Active, not recruiting
Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Start of enrollment: 2021 May 07
Recruiting
Phase 2
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy Start of enrollment: 2022 Sep 30
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric mo...
Reza Zarinshenas, Peter Campbell, Kai Sun, Jason K Molitoris, Akshar N Patel, Matthew E Witek, Kevin J Cullen, Ranee Mehra, Kyle M Hatten, Kelly F Moyer, Rodney J Tayl...> ;Radiotherapy and Oncology. 2024 Apr 1
The role of surgery and deescalation for HPV-related oropharyngeal cancer.
Kevin J Contrera, Mihir R Patel, Robert L Ferris, Barbara Burtness, Ranee Mehra> ;Cancer. 2024 Mar 18
Radiomic Biomarkers of Locoregional Recurrence: Prognostic Insights from Oral Cavity Squamous Cell Carcinoma preoperative CT scans.
Ren, L., Ling, X., Alexander, G., Molitoris, J., Choi, J., Schumaker, L., Gaykalova, D., Mehra, R.> ;Research Square. 2024 Jan 22
Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma.
Fernando Zamuner, Stephanie Ting, Pablo Tamayo, Daria Gaykalova, Theresa Guo, Liam Chen, Lisa Rooper, Carole Fakhry, Ranee Mehra> ;Frontiers in Oncology. 2024 Jan 1
1 citations
Identification of CT-based non-invasive radiomic biomarkers for overall survival prediction in oral cavity squamous cell carcinoma.
Ling, X., Choi, J., Schumaker, L., Gaykalova, D., Ren, L., Alexander, G., Molitoris, J., Mehra, R.> ;Scientific Reports. 2023 Dec 8
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
Diego de Miguel-Perez, Edward M Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A Pinto, Alessandro Russo, Gianca...> ;European Journal of Cancer. 2024 Jan 1
Identification of CT-based non-invasive Radiographic Biomarkers for Overall Survival Stratification in Oral Cavity Squamous Cell Carcinoma.
Xiao Ling, Gregory S Alexander, Jason Molitoris, Jinhyuk Choi, Lisa Schumaker, Ranee Mehra, Daria A Gaykalova, Lei Ren> ;Research Square. 2023 Aug 23
1 citations
Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.
Alessandro Russo, Katherine A Scilla, Ranee Mehra, Allison Gittens, Michael G McCusker, Diego de Miguel-Perez, Jorge E Gomez, Ariel Peleg, Marzia Del Re, Christian D R...> ;Clinical Lung Cancer. 2023 Nov 1
5 citations
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Jong Chul Park, Harriet Kluger, Hu...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
2 citations
Regionalization of Head and Neck Oncology Tumor Boards: Perspectives of Collaborating Physicians.
Neha B Amin, Kelly M Bridgham, Jessica P Brown, Kelly F Moyer, Rodney J Taylor, Jeffrey S Wolf, Matthew E Witek, Jason K Molitoris, Ranee Mehra, Kevin J Cullen, John C...> ;OTO Open. 2023 Feb 28
1 citations
Gross tumor volume margin and local control in p16-positive oropharynx cancer patients treated with intensity modulated proton therapy.
Danielle Arons, Gregory S Alexander, David Alicia, Kayla M Birkman, Jason K Molitoris, Ranee Mehra, Kevin J Cullen, Kyle M Hatten, Rodney J Taylor, Jeffrey S Wolf, Wil...> ;Head & Neck. 2023 May 1
The Effect of Body Mass Index and Residence in Food Priority Areas on Patterns-of-Care and Cancer Outcomes in Patients With Stage III Non-Small Cell Lung Cancer.
Bansi Savla, M A Hamza, D Yacubovich, S Cobbs, L Petrovska, K A Scilla, W Burrows, R Mehra, R C Miller, C Rolfo, S M Bentzen, P Mohindra, Melissa A L Vyfhuis> ;International Journal of Radiation Oncology, Biology, Physics. 2023 May 1
8 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra, Laura Q M Chow, Stephen V Liu, Hyunseok Kang, Nabil F Saba, Lori J Wirth, Ammar Sukari, E...> ;Cancer Medicine. 2023 Mar 1
1 citations
Human Papillomavirus Impact on Temporal Treatment Trends in Oropharyngeal Carcinoma: 2010-2016.
Neha Amin, Joshua Thompson, Olga Goloubeva, Matthew Witek, Rodney J Taylor, Jeffrey S Wolf, Kelly Moyer, Ranee Mehra, Kyle M Hatten> ;ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties. 2022 Jan 1
1 citations
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Gallow...> ;Journal of the National Cancer Institute. 2022 Dec 8
4 citations
Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
Zejia Yang, Jipei Liao, Lisa Schumaker, Brandon Carter-Cooper, Rena G Lapidus, Xiaoxuan Fan, Daria A Gaykalova, Ranee Mehra, Kevin J Cullen, Hancai Dan> ;Oral Oncology. 2022 Aug 1
1 citations
Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer.
Husam Albarmawi, Kevin J Cullen, Ranee Mehra, Eberechukwu Onukwugha, Olga Goloubeva> ;Journal of Comparative Effectiveness Research. 2022 Jun 1
2 citations
Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Zejia Yang, Jipei Liao, Rena G Lapidus, Xiaoxuan Fan, Ranee Mehra, Kevin J Cullen, Hancai Dan> ;Cancer Chemotherapy and Pharmacology. 2022 Apr 1
13 citations
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, E P Mitchell, J J Wright, N Takebe, E Sharon, D Hovelson, S Tomlins, J Zeng, K Poorman, N Mal...> ;NPJ Precision Oncology. 2022 Mar 1
2 citations
Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment.
Michael G McCusker, Ranee Mehra, Sania Amr, Rodney J Taylor, Kevin J Cullen, Olga G Goloubeva> ;Head & Neck. 2022 Mar 1
35 citations
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, ...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
1 citations
Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
Candice Yong, M Janelle Cambron-Mellott, Brian Seal, Oliver Will, Martine C Maculaitis, Kelly Clapp, Emily Mulvihill, Ion Cotarla, Ranee Mehra> ;Patient Preference and Adherence. 2022 Jan 1
4 citations
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
D.S-W. Tan, Michael Thomas, D-W. Kim, Sebastian Szpakowski, Patrick Urban, Ranee Mehra, Laura Q.M. Chow, Sunil Sharma, Ben Solomon, Enriqueta Felip, D.R. Camidge, Joha...> ;Lung Cancer. 2021 Nov 20
114 citations
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN ...
Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri,...> ;Journal of Clinical Oncology. 2021 Oct 26
4 citations
Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma
Sania Amr, Dina Ioffe, Ikumi Suzuki, Ranee Mehra, Kevin J. Cullen, Olga Goloubeva> ;Head & Neck. 2021 Oct 10
Join now to see all

Journal Articles

Pattern of Planned Systemic Therapy Usage in Newly Diagnosed, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck in a Commercially Insured Population in the Un...
Christine G Gourin, Ranee Mehra, Hyunseok Kang, Arlene A Forastiere, Ana P Kiess, Head & Neck

Press Mentions

Head and Neck Cancer Awareness Month: 2020 Immunotherapy Research UpdateApril 14th, 2020
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaSeptember 7th, 2017
Pembrolizumab and Cetuximab-Treated Head and Neck Cancer: Activity Confirmed but No SurprisesJuly 25th, 2017
Join now to see all